Following a novel analgesic from target ID to clinical trials
Only 2% of novel analgesics will make it through clinical development. Understanding the development process for an individual pain...
Expert views on Analgesic News
Following a novel analgesic from target ID to clinical trials
Complex 3D human model systems to bridge the translation gap in pain.
New study highlights need for female-focused research
Vertex unlikely to repeat their CF success in Pain as they lack a personalized analgesics® approach.
How to improve innovation in analgesic development: Poster presented at IASP virtual Meeting 2020.
Peripherally acting phase 1 pain drug acquired in $940Million deal.
Unity Bio's novel pain drug fails in OA. Did they miss out by not using a precision approach?
FDA approves Trevena’s Mu opioid for Acute pain.
NICE guidance on chronic pain could prevent patients receiving life altering treatments
P2X3 cough drug: Negative Ph II = 70% loss of stock price but severe patient group may show the way.
Biogen ready to write-off Nav1.7 assets in pain?
Revolutionising pain R&D by developing Precision Analgesics
COVID19: creating a new era for 'Citizen Science'
P2X3 receptor antagonists pass Phase 3 trials for cough – potential also in pain?
Which companies are interested in Pain? The useful analytics below LinkedIn likes & comments.
Is this still a relevant target for new pain treatments: the α2δ (Alpha2Delta) Ca2+ channel?
Has a new study found a personalized approach for Nav1.7? 'Precision Analgesics' may be a better bet
So Pfizer & Lilly do ask FDA to approve Tanezumab for OA pain...
Vertex discontinues development of its Nav1.8 pain drug VX-961.
Big data & human biomarkers – the era of citizen scientists